Table 2.
Population characteristics of asthmatic children and young adults who underwent genotyping for CYP3A polymorphisms
| Variables | Number (%) |
|---|---|
| Total no. of subjects | 734 |
| Subjects receiving daily inhaled glucocorticoids | 413 (56.3) |
| Fluticasone propionate | 268 (36.5) |
| Flunisolide | 10 (1.4) |
| Triamcinolone acetonide | 2 (0.3) |
| Beclomethasone dipropionate | 31 (4.2) |
| Budesonide | 56 (7.6) |
| Ciclesonide | 2 (0.3) |
| Mometasone | 7 (1.0) |
| Fluticasone propionate / salmeterol xinafoate | 82 (11.2) |
| Budesonide / formoterol | 11 (1.5) |
| Age, yrs | 8.8 ± 4.3 |
| Sex | |
| Male | 443 (60.5) |
| Female | 289 (39.5) |
| Race | |
| American Indian / Alaskan Native | 9 (1.2) |
| Asian | 6 (0.8) |
| Black | 24 (3.3) |
| Native Hawaiian / Pacific Islander | 15 (2.0) |
| White | 554 (75.5) |
| Unknown / Not reported | 122 (16.6) |
| Ethnicity | |
| Hispanic | 102 (14.0) |
| Non-Hispanic | 211 (28.9) |
| Unknown / Not reported | 418 (57.2) |
| Weight, kg | 35.1 ± 21.6 |
| Height, cm | 124.9 ±.26.6 |
| Asthma control score | |
| Subjects receiving daily fluticasone | 4.8 ± 3.6 |
| Subjects receiving other inhaled glucocorticoids | 4.9 ± 3.6 |
NOTE: Values are presented as mean + SD where applicable.